Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9081984 | 1.00 | MDM4 (0.53) | MDM4TP53MDM2ADAM17CASP3 | |
| SCHEMBL9113360 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL120776 | 0.88 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL13964946 | 0.88 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL15521164 | 0.88 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL14037136 | 0.88 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL119657 | 0.88 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL31370341 | 0.88 | MDM4 (0.51) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL29601670 | 0.88 | MDM4 (0.52) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL26008959 | 0.87 | MDM4 (0.50) | MDM4TP53MDM2CASP3SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104021-A1 | METABOLIC CHECKPOINT-BASED HUMAN SERUM ALBUMIN NANO-DRUG, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳先进技术研究院 | 2023-06-15 | — | — | WO | disclosed |
| WO-2023102507-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023288213-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-19 | — | — | WO | disclosed |
| CN-114306620-A | Human serum albumin nano-drug based on metabolism check point and preparation method and application thereof | 深圳先进技术研究院 | 2022-04-12 | — | — | CN | disclosed |
| US-9512180-B2 | Compstatin analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150329594-A1 | COMPSTATIN ANALOGS | UNIVERSITY OF CYPRUS (CY) | 2015-11-19 | — | — | US | disclosed |
| CN-1964955-A | Small molecules for treatment of hypercholesterolemia and related diseases | AVANIR PHARMACEUTICALS (US) | 2007-05-16 | — | — | CN | disclosed |
| EP-1753733-A1 | SMALL MOLECULES FOR TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED DISEASES | Avanir Pharmaceuticals (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005123700-A1 | SMALL MOLECULES FOR TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED DISEASES | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050277690-A1 | Small molecules for treatment of hypercholesterolemia and related diseases | AVANIR PHARMACEUTICALS | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277690-A1 | Small molecules for treatment of hypercholesterolemia and related diseases | LDLR, NPC1L1, CETP | MDM4 4337/4885TP53 3217/4885MDM2 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.